Smruthi Organics Limited (BOM:540686)

Market Cap	1.40B -0.2%
Revenue (ttm)	1.11B -13.0%
Net Income	45.89M +60.9%
EPS	4.02 +61.7%
Shares Out	11.45M
PE Ratio	30.53
Forward PE	n/a
Dividend	1.50 (1.22%)
Ex-Dividend Date	Jun 13, 2025

Volume	4,024
Average Volume	4,025
Open	126.35
Previous Close	126.35
Day's Range	121.25 - 128.40
52-Week Range	103.00 - 164.00
Beta	-0.42
RSI	59.35
Earnings Date	Feb 13, 2026

About Smruthi Organics

Smruthi Organics Limited manufactures and markets active pharmaceutical ingredient (API) products to India. The company provides API for cardiovascular that includes amlodipine besilate, losartan potassium, telmisartan, s - amlodipine besilate, s - amlodipine malelate, and valsartan; for anti diabetic, which comprises metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; and for anti infectives that consists of ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate, as well as ticagrelor for anti platelets. It also...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 267
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540686

Financial Performance

In fiscal year 2025, Smruthi Organics's revenue was 1.26 billion, a decrease of -1.28% compared to the previous year's 1.28 billion. Earnings were 35.63 million, a decrease of -0.76%.